http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2018204345-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0982693d86cd4ee668f7595dfacba4aa |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2018-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c68c8539d31dc2b684e15676dbecb24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b36df3cf42153fe5aca1845218c485e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0daaf56c8dce4e9e901f5227ee652c03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e94faa38b27bdf02cf3e2f91a61d15d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5853d77f48201b231849242280fb87be http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8cd31318dc2ede2c9f4baf1892fcb2ed http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5cdb6afa435113e527da048dbc95bc1a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1702203a5c2292eb9b08590815a6c9a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_664fd3fcb996820318d9be6dcada7cbc |
| publicationDate | 2018-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2018204345-A1 |
| titleOfInvention | Antibodies to IL-6 and use thereof |
| abstract | Abstract The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others. Additional preferred embodiments of the subject invention relate to therapeutic compositions and methods treating or preventing rheumatoid arthritis, especially subcutaneous and intravenous formulations and dosage regimens using IL-6 antagonists according to the invention, as well as methods for preventing or treating GVHD or leukemia relapse in subjects receiving transplanted cells, tissue or organs, use thereof in the treatment or prevention of mucositis, and use thereof to potentiate the cytotoxic, apoptotic, and anti-metastatic or anti-invasive effects of chemotherapeutics and radiation on cancers, especially cancers that have developed a resistance to radiation or chemotherapy, such as an EGFR inhibitor. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022147509-A1 |
| priorityDate | 2009-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 2577.